Part I . Overview We are a biotechnology company focused on identifying and advancing innovative therapeutic opportunities. In January 2026 we announced our wholly owned subsidiary, Axion Bio, Inc., or Axion Bio, was discontinuing development of our former lead product candidate, AXN-2510, a bispecific antibody targeting both programmed death-ligand 1 and the family of vascular endothelial growth factors in solid tumor cancers. Axion Bio in-licensed AXN-2510 from ImmuneOnco Biopharmaceuticals (S...
Q2 FY2026 — expected 2026-08-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001789769-26-000019 | EDGAR | 69K words |
| 2025-03-04 | 2024-12-31 | 0001789769-25-000017 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0001789769-24-000036 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001789769-23-000035 | EDGAR | — |
| 2022-03-07 | 2021-12-31 | 0001789769-22-000008 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-13 | 2025-09-30 | 0001789769-25-000094 | EDGAR | 59K words |
| 2025-08-13 | 2025-06-30 | 0001789769-25-000081 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0001789769-25-000051 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0001789769-24-000103 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001789769-24-000086 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001789769-24-000059 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001789769-23-000091 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0001789769-23-000085 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0001789769-23-000069 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0001789769-22-000098 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001789769-22-000069 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0001789769-22-000032 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-03 | 0001789769-26-000024 | EDGAR | 1K words |
| 2026-03-27 | 0001789769-26-000018 | EDGAR | — |
| 2026-01-06 | 0001789769-26-000004 | EDGAR | — |
| 2025-11-13 | 0001789769-25-000092 | EDGAR | — |
| 2025-08-13 | 0001789769-25-000079 | EDGAR | — |
| 2025-07-31 | 0001789769-25-000074 | EDGAR | — |
| 2025-05-28 | 0001789769-25-000062 | EDGAR | — |
| 2025-05-27 | 0001789769-25-000059 | EDGAR | — |
| 2025-05-22 | 0001789769-25-000054 | EDGAR | — |
| 2025-05-13 | 0001789769-25-000050 | EDGAR | — |
94 total filings indexed. 67 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001789769 |
| Ticker | TIL |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | NY |
| Website | https://www.instilbio.com |
| Listed | 2021-03-19 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/TIL (~200 tokens, structured JSON with cryptographic provenance)